AstraZeneca's Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in the US for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or
On November 13, 2023, Lufax Holding Ltd (“Lufax” or the “Company”) entered into a share purchase agreement (the “Share Purchase Agreement”) with OneConnect Financial Technology
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) today announced positive Phase 2 data that show etripamil nasal spray resulted in rapid and statistically superior ventricular rate reduction and improved symptom-relief in
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced the completion of enrollment and positive preliminary findings from Part 1 of the ongoing HALOS Phase 1/2a study of ION582 (BIIB121) in Angelman syndrome. ION582
BridgeBio Pharma, Inc. (NASDAQ:BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today presented additional Phase 3
Today, U.S. Data Mining Group, Inc. d/b/a US Bitcoin Corp (USBTC) announces two significant developments: the progression of its merger with Hut 8 Mining Corp (“Hut 8”) and court approval of the Celsius
Novo Nordisk today announced plans to invest more than 42 billion Danish kroner starting in 20231 to expand existing manufacturing facilities in Kalundborg, Denmark, for the current and future product portfolio within
Initial data from the combination of imdusiran and VTP-300 show meaningful reductions of HBsAg levels that were maintained well below baseline.
In HBV003, 31% of participants with screening HBsAg level of ≤200
Worthington Industries, Inc. (“Worthington Industries” or the “Company”) (NYSE:WOR), a leading industrial manufacturer, today announced that its Board of Directors (the “Board”)